Single-centre experience with intradetrusor injection of onabotulinumtoxinA: a retrospective study of the years 2003–2012 in a Danish population

Autor: Jacob Juel, Frederikke Eichner Christiansen, Torben Pedersen, Hans Jørgen Kirkeby
Rok vydání: 2017
Předmět:
Male
Time Factors
Denmark
Acetylcholine Release Inhibitors
030232 urology & nephrology
Urinary incontinence
PLACEBO-CONTROLLED TRIAL
DOUBLE-BLIND
0302 clinical medicine
Botulinum Toxins
Type A
urinary incontinence
Urinary bladder
neurogenic bladder
Middle Aged
Single centre
Treatment Outcome
medicine.anatomical_structure
Overactive bladder
Nephrology
SAFETY
030220 oncology & carcinogenesis
Urinary Tract Infections
Female
URINARY-INCONTINENCE
medicine.symptom
urinary bladder
Adult
medicine.medical_specialty
PHASE-3
Urology
BOTULINUM-TOXIN
Injections
Intramuscular
TOXIN TYPE-A
03 medical and health sciences
NEUROGENIC DETRUSOR OVERACTIVITY
Internal medicine
medicine
Humans
Intermittent Urethral Catheterization
Urinary Bladder
Neurogenic
Botulinum toxin A
Adverse effect
Aged
Hematuria
Retrospective Studies
Urinary Bladder
Overactive
Urinary retention
business.industry
Retrospective cohort study
BLADDER
Urinary Retention
EFFICACY
medicine.disease
Surgery
Urinary Incontinence
Telephone interview
overactive bladder
business
Zdroj: Christiansen, F E, Pedersen, T B, Juel, J & Kirkeby, H J 2017, ' Single-centre experience with intradetrusor injection of onabotulinumtoxinA : a retrospective study of the years 2003-2012 in a Danish population ', Scandinavian Journal of Urology and Nephrology, vol. 51, no. 5, pp. 392-396 . https://doi.org/10.1080/21681805.2017.1329228
ISSN: 2168-1813
2168-1805
DOI: 10.1080/21681805.2017.1329228
Popis: Objective: This study aimed to evaluate the efficacy of treatment for incontinence due to neurogenic detrusor overactivity (NDO) and idiopathic detrusor overactivity (IDO) with onabotulinumtoxinA (BoNT-A) at Aarhus University Hospital, Skejby, Denmark.Materials and methods: The data were collected retrospectively by systematic review of the patient records from March 2003 to May 2012. Patients treated with BoNT-A over the age of 18years were included. Treatment indication, diagnosis, adverse events, treatment interval, duration of effect and effect grade were registered. Follow-up data were collected by a telephone interview 4weeks after treatment.Results: The study identified 219 patients, who received a total of 657 treatments during the period. Full effect of the treatment was experienced in 71%, intermediate effect was seen in 16% and low effect in 3%. There was no difference in effect duration between the IDO and NDO groups. The most common adverse event was the need to perform clean intermittent self-catheterization; 27% of all patients experienced this. Urinary tract infections were reported in 5% of procedures and significant haematuria in 1%. These findings correspond with the results of other published studies.Conclusion: BoNT-A is a safe and effective treatment for incontinence in IDO and NDO.
Databáze: OpenAIRE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje